Oritavancin < em > in vitro < /em > activity against Gram-positive organisms from European medical centers: a 10-year longitudinal overview from the SENTRY Antimicrobial Surveillance Program (2010-2019)
J Chemother. 2023 Sep 25:1-11. doi: 10.1080/1120009X.2023.2259673. Online ahead of print.ABSTRACTTo assess oritavancin in vitro activity against clinically relevant Gram-positive pathogens in European (EU) hospitals, a total of 51,531 consecutive and unique clinical isolates collected in 2010-2019 were evaluated. All isolates were tested by CLSI broth microdilution methods. The key resistance phenotypes differed considerably between Eastern Europe (E-EU) and Western Europe (W-EU), respectively: methicillin-resistant (MR) Staphylococcus aureus 27.7%/22.9%; multidrug resistant (MDR) S. aureus, 19.7%/15.2%; MR coagulase-negat...
Source: Journal of Chemotherapy - September 25, 2023 Category: Cancer & Oncology Authors: M A Pfaller R E Mendes H S Sader M Castanheira C G Carvalhaes Source Type: research
CircAGFG1 absence decreases PKM2 expression to enhance oxaliplatin sensitivity in colorectal cancer in a miR-7-5p-dependent manner
J Chemother. 2023 Sep 10:1-14. doi: 10.1080/1120009X.2023.2253680. Online ahead of print.ABSTRACTCircular RNA (circRNA) ArfGAP with FG repeats 1 (circAGFG1) contributes to colorectal cancer (CRC) development. However, whether circAGFG1 regulates the resistance of CRC to oxaliplatin (L-OHP) remains unknown. CircAGFG1, microRNA-7-5p (miR-7-5p) and pyruvate kinase M2 (PKM2) RNA expression were quantified by quantitative real-time polymerase chain reaction. Protein expression was detected by western blot assay and immunohistochemistry assay. Glycolysis was analyzed through glucose uptake, lactate production and adenosine triph...
Source: Journal of Chemotherapy - September 11, 2023 Category: Cancer & Oncology Authors: Jun Chen Hongwei Wang Mingsheng Tang Source Type: research
